What is the specific drug policy for veentuzumab/besifux?

Enfortumab is an antibody-drug conjugate (ADC) that targets the nectin-4 target in urothelial cancer. It combines the targeting of monoclonal antibodies with the cytotoxicity of microtubule inhibitors. It is used to treat patients with advanced or metastatic urothelial cancer (bladder cancer), especially those who are resistant to chemotherapy and immune checkpoint inhibitors.

In terms of drug policy, venetuzumab has been approved for marketing in China, but due to its short time on the market, its medical insurance and price policies are still in the exploratory stage. Current domestic policies emphasize its use in specialized hospitals and cancer centers and must meet specific indications, that is, it can only be used by patients with advanced or metastatic urothelial cancer whose disease has progressed after previous chemotherapy and immunotherapy.

Overseas, veentuzumab has been included in the national medical insurance and drug reimbursement systems of some countries, but the reimbursement conditions are strict. Patients must have a clear history of chemotherapy and PD-1/PD-L1 inhibitor treatment, and the condition is still progressing as confirmed by imaging or clinical studies. In order to ensure the rational use of drugs, policies usually require treatment centers to register and monitor patients, evaluate efficacy and tolerability, and avoid inappropriate use. In addition, some countries have also established patient assistance programs to help reduce the out-of-pocket burden of drugs. Future domestic medical insurance negotiations and drug policies may refer to overseas experience and take into account drug accessibility and affordability through limited restrictions, conditional reimbursement and patient assistance projects.

The policy level also emphasizes safety monitoring. Since venetuzumab may cause adverse reactions such as rash, peripheral neuropathy, and abnormal blood sugar, hospitals need to establish a complete medication management and adverse event reporting mechanism to ensure that patients receive continuous medical evaluation during the treatment process.

Reference: https://www.padcev.com/